A team of biotech veterans say they have raised $3 billion to create a continent-spanning company that will aim to battle disease by reprogramming the fundamental machinery of living cells.
It appears to be the largest venture capital fundraising effort in biotech history, based on a survey of data from Pitchbook.
The company, Altos Labs, is the brainchild of Richard Klausner, a serial biotech entrepreneur who has previously founded two biotechnology companies that raised large sums of money and were sold to larger firms. Klausner is being joined by Hans Bishop, who served as CEO of those companies, Juno Biotechnology and Grail. And Hal Barron, the chief scientific officer of GlaxoSmithKline, will join as the new company’s CEO in August.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
